Turning enzymes on with small molecules

Nature Chemical Biology

Volumn 6, Issue 3, 2010, Pages 179-188

  Zorn, Julie A ^a   Wells, James A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ADENYLATE KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENZYME ACTIVATOR; GLUCOKINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROCASPASE 3; PS 48; PT 1; RESVERATROL; RIBONUCLEASE L; RO 281675; SIRTUIN; SIRTUIN 1; SRT 1720; SRTI 720; UNCLASSIFIED DRUG;

ALLOSTERISM; BINDING AFFINITY; CATALYSIS; CONFORMATIONAL TRANSITION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME SUBSTRATE COMPLEX; OLIGOMERIZATION; PRIORITY JOURNAL; REVIEW;

EID: 77249169281     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.318     Document Type: Review

References (109)

1. Alaimo, P.J., Shogren-Knaak, M.A. & Shokat, K.M. Chemical genetic approaches for the elucidation of signaling pathways. Curr. Opin. Chem. Biol. 5, 360-367 (2001).
2. Cravatt, B.F. & Sorensen, E.J. Chemical strategies for the global analysis of protein function. Curr. Opin. Chem. Biol. 4, 663-668 (2000).
3. Stockwell, B.R. Chemical genetics: ligand-based discovery of gene function. Nat. Rev. Genet. 1, 116-125 (2000).
4. Cárdenas, M.L. & Cornish-Bowden, A. Characteristics necessary for an interconvertible enzyme cascade to generate a highly sensitive response to an effector. Biochem. J. 257, 339-345 (1989).
5. Goldbeter, A. & Koshland, D.E. Sensitivity amplification in biochemical systems. Q. Rev. Biophys. 15, 555-591 (1982).
6. Szedlacsek, S.E., Cárdenas, M.L. & Cornish-Bowden, A. Response coefficients of interconvertible enzyme cascades towards effectors that act on one or both modifier enzymes. Eur. J. Biochem. 204, 807-813 (1992).
7. Bishop, A.C. & Chen, V.L. Brought to life: targeted activation of enzyme function with small molecules. J. Chem. Biol. 2, 1-9 (2009).
8. Cárdenas, M.L., Cornish-Bowden, A. & Ureta, T. Evolution and regulatory role of the hexokinases. Biochim. Biophys. Acta 1401, 242-264 (1998).
9. Matschinsky, F. Assessing the potential of glucokinase activators in diabetes therapy. Nat. Rev. Drug Discov. 8, 399-416 (2009).
10. Pal, M. Recent advances in glucokinase activators for the treatment of type 2 diabetes. Drug Discov. Today 14, 784-792 (2009).
11. Matschinsky, F.M. et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 55, 1-12 (2006).
12. Gidh-Jain, M. et al. Glucokinase mutations associated with non-insulindependent (type 2) diabetes mellitus have decreased enzymatic activity: implications for structure/function relationships. Proc. Natl. Acad. Sci. USA 90, 1932-1936 (1993).
13. de la Iglesia, N., Veiga-da-Cunha, M., Van Schaftingen, E., Guinovart, J.J. & Ferrer, J.C. Glucokinase regulatory protein is essential for the proper subcellular localisation of liver glucokinase. FEBS Lett. 456, 332-338 (1999).
14. Anderka, O. et al. Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: impact of physiological and pharmacological effectors. J. Biol. Chem. 283, 31333-31340 (2008).
15. Veiga-da-Cunha, M. & Van Schaftingen, E. Identification of fructose 6-phosphate- and fructose 1-phosphate-binding residues in the regulatory protein of glucokinase. J. Biol. Chem. 277, 8466-8473 (2002).
16. Grimsby, J. et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301, 370-373 (2003).
17. Ralph, E.C., Thomson, J., Almaden, J. & Sun, S. Glucose modulation of glucokinase activation by small molecules. Biochemistry 47, 5028-5036 (2008).
18. Guertin, K.R. & Grimsby, J. Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. Curr. Med. Chem. 13, 1839-1843 (2006).
19. Kamata, K., Mitsuya, M., Nishimura, T., Eiki, J.-I. & Nagata, Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 12, 429-438 (2004).
20. Milne, J.C. & Denu, J.M. The Sirtuin family: therapeutic targets to treat diseases of aging. Curr. Opin. Chem. Biol. 12, 11-17 (2008).
21. Longo, V.D. & Kennedy, B.K. Sirtuins in aging and age-related disease. Cell 126, 257-268 (2006).
22. Kaeberlein, M., McVey, M. & Guarente, L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 13, 2570-2580 (1999).
23. Lin, S.J., Defossez, P.A. & Guarente, L. Requirement of NAD and SIR2 for lifespan extension by calorie restriction in Saccharomyces cerevisiae. Science 289, 2126-2128 (2000).
24. Cohen, H.Y. et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305, 390-392 (2004).
25. Lavu, S., Boss, O., Elliott, P.J. & Lambert, P.D. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug Discov. 7, 841-853 (2008).
26. Kaeberlein, M., Kirkland, K.T., Fields, S. & Kennedy, B.K. Sir2-independent life span extension by calorie restriction in yeast. PLoS Biol. 2, E296 (2004).
27. Finkel, T., Deng, C.-X. & Mostoslavsky, R. Recent progress in the biology and physiology of sirtuins. Nature 460, 587-591 (2009).
28. Anderson, R.M., Bitterman, K.J., Wood, J.G., Medvedik, O. & Sinclair, D.A. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature 423, 181-185 (2003).
29. Kim, J.-E., Chen, J. & Lou, Z. DBC1 is a negative regulator of SIRT1. Nature 451, 583-586 (2008).
30. Zhao, W. et al. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 451, 587-590 (2008).
31. Kim, E.-J., Kho, J.-H., Kang, M.-R. & Um, S.-J. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol. Cell 28, 277-290 (2007).
32. Smith, B.C., Hallows, W.C. & Denu, J.M. Mechanisms and molecular probes of sirtuins. Chem. Biol. 15, 1002-1013 (2008).
33. Howitz, K.T. et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196 (2003).
34. Kaeberlein, M. et al. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 280, 17038-17045 (2005).
35. Milne, J.C. et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712-716 (2007).
36. Pacholec, M. et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. published online, doi:10.1074/jbc. M109.088682 (8 January 2010).
37. Frödin, M. et al. A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation. EMBO J. 21, 5396-5407 (2002).
38. Huse, M. & Kuriyan, J. The conformational plasticity of protein kinases. Cell 109, 275-282 (2002).
39. Biondi, R.M. Phosphoinositide-dependent protein kinase 1, a sensor of protein conformation. Trends Biochem. Sci. 29, 136-142 (2004).
40. Biondi, R.M. et al. High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site. EMBO J. 21, 4219-4228 (2002).
41. Biondi, R.M. et al. Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA. EMBO J. 19, 979-988 (2000).
42. Engel, M. et al. Allosteric activation of the protein kinase PDK1 with low molecular weight compounds. EMBO J. 25, 5469-5480 (2006).
43. Stroba, A. et al. 3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds. J. Med. Chem. 52, 4683-4693 (2009).
44. Hindie, V. et al. Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. Nat. Chem. Biol. 5, 758-764 (2009).
45. Biondi, R.M., Kieloch, A., Currie, R.A., Deak, M. & Alessi, D.R. The PIFbinding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J. 20, 4380-4390 (2001).
46. Pellicena, P. & Kuriyan, J. Protein-protein interactions in the allosteric regulation of protein kinases. Curr. Opin. Struct. Biol. 16, 702-709 (2006).
47. Tappan, E. & Chamberlin, A.R. Activation of protein phosphatase 1 by a small molecule designed to bind to the enzyme's regulatory site. Chem. Biol. 15, 167-174 (2008).
48. Balasubramanyam, K., Swaminathan, V., Ranganathan, A. & Kundu, T.K. Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem. 278, 19134-19140 (2003).
49. Reineke, J. et al. Autocatalytic cleavage of Clostridium difficile toxin B. Nature 446, 415-419 (2007).
50. Egerer, M., Giesemann, T., Jank, T., Satchell, K.J.F. & Aktories, K. Autocatalytic cleavage of Clostridium difficile toxins A and B depends on cysteine protease activity. J. Biol. Chem. 282, 25314-25321 (2007).
51. Egerer, M., Giesemann, T., Herrmann, C. & Aktories, K. Autocatalytic processing of Clostridium difficile toxin B. Binding of inositol hexakisphosphate. J. Biol. Chem. 284, 3389-3395 (2009).
52. Lupardus, P.J., Shen, A., Bogyo, M. & Garcia, K.C. Small molecule-induced allosteric activation of the Vibrio cholerae RTX cysteine protease domain. Science 322, 265-268 (2008).
53. Shen, A. et al. Mechanistic and structural insights into the proteolytic activation of Vibrio cholerae MARTX toxin. Nat. Chem. Biol. 5, 469-478 (2009).
54. Prochazkova, K. & Satchell, K.J.F. Structure-function analysis of inositol hexakisphosphate-induced autoprocessing of the Vibrio cholerae multifunctional autoprocessing RTX toxin. J. Biol. Chem. 283, 23656-23664 (2008).
55. Prochazkova, K. et al. Structural and molecular mechanism for autoprocessing of MARTX toxin of Vibrio cholerae at multiple sites. J. Biol. Chem. 284, 26557-26568 (2009).
56. Pop, C. & Salvesen, G. Human caspases: activation, specificity and regulation. J. Biol. Chem. 284, 21777-21781 (2009).
57. Creagh, E.M., Conroy, H. & Martin, S.J. Caspase-activation pathways in apoptosis and immunity. Immunol. Rev. 193, 10-21 (2003).
58. Yi, C.H. & Yuan, J. The Jekyll and Hyde functions of caspases. Dev. Cell 16, 21-34 (2009).
59. Stennicke, H.R. & Salvesen, G.S. Caspases - controlling intracellular signals by protease zymogen activation. Biochim. Biophys. Acta 1477, 299-306 (2000).
60. Earnshaw, W.C., Martins, L.M. & Kaufmann, S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 68, 383-424 (1999).
61. Salvesen, G.S. & Riedl, S.J. Caspase mechanisms. Adv. Exp. Med. Biol. 615, 13-23 (2008).
62. Roy, S. et al. Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide. Proc. Natl. Acad. Sci. USA 98, 6132-6137 (2001).
63. Hardy, J.A., Lam, J., Nguyen, J.T., O'Brien, T. & Wells, J.A. Discovery of an allosteric site in the caspases. Proc. Natl. Acad. Sci. USA 101, 12461-12466 (2004).
64. Scheer, J.M., Romanowski, M.J. & Wells, J.A. A common allosteric site and mechanism in caspases. Proc. Natl. Acad. Sci. USA 103, 7595-7600 (2006).
65. Gao, J., Sidhu, S.S. & Wells, J.A. Two-state selection of conformation-specific antibodies. Proc. Natl. Acad. Sci. USA 106, 3071-3076 (2009).
66. Chai, J. et al. Crystal structure of a procaspase-7 zymogen: mechanisms of activation and substrate binding. Cell 107, 399-407 (2001).
67. Riedl, S.J. et al. Structural basis for the activation of human procaspase-7. Proc. Natl. Acad. Sci. USA 98, 14790-14795 (2001).
68. Putt, K.S. et al. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat. Chem. Biol. 2, 543-550 (2006).
69. Denault, J.-B. et al. Small molecules not direct activators of caspases. Nat. Chem. Biol. 3, 519 (2007); author reply 3, 520 (2007).
70. Peterson, Q.P. et al. PAC-1 activates procaspase-3 in vitro through relief of zincmediated inhibition. J. Mol. Biol. 388, 144-158 (2009).
71. Wolan, D.W., Zorn, J.A., Gray, D.C. & Wells, J.A. Small-molecule activators of a proenzyme. Science 326, 853-858 (2009).
72. Svingen, P.A. et al. Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel. Clin. Cancer Res. 10, 6807-6820 (2004).
73. Zhang, B.B., Zhou, G. & Li, C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 9, 407-416 (2009).
74. Hardie, D.G. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144, 5179-5183 (2003).
75. Hardie, D.G. AMP-activated protein kinase as a drug target. Annu. Rev. Pharmacol. Toxicol. 47, 185-210 (2007).
76. Amodeo, G.A., Rudolph, M.J. & Tong, L. Crystal structure of the heterotrimer core of Saccharomyces cerevisiae AMPK homologue SNF1. Nature 449, 492-495 (2007).
77. Crute, B.E., Seefeld, K., Gamble, J., Kemp, B.E. & Witters, L.A. Functional domains of the alpha1 catalytic subunit of the AMP-activated protein kinase. J. Biol. Chem. 273, 35347-35354 (1998).
78. Chen, L. et al. Structural insight into the autoinhibition mechanism of AMPactivated protein kinase. Nature 459, 1146-1149 (2009).
79. Xiao, B. et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature 449, 496-500 (2007).
80. Townley, R. & Shapiro, L. Crystal structures of the adenylate sensor from fission yeast AMP-activated protein kinase. Science 315, 1726-1729 (2007).
81. Kahn, B.B., Alquier, T., Carling, D. & Hardie, D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1, 15-25 (2005).
82. Sabina, R.L., Holmes, E.W. & Becker, M.A. The enzymatic synthesis of 5-amino-4-imidazolecarboxamide riboside triphosphate (ZTP). Science 223, 1193-1195 (1984).
83. Corton, J.M., Gillespie, J.G., Hawley, S.A. & Hardie, D.G. 5-aminoimidazole-4- carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229, 558-565 (1995).
84. Cool, B. et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3, 403-416 (2006).
85. Göransson, O. et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J. Biol. Chem. 282, 32549-32560 (2007).
86. Scott, J.W. et al. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem. Biol. 15, 1220-1230 (2008).
87. Sanders, M.J. et al. Defining the mechanism of activation of AMPactivated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J. Biol. Chem. 282, 32539-32548 (2007).
88. Zhao, G. et al. Discovery and SAR development of thienopyridones: a class of small molecule AMPK activators. Bioorg. Med. Chem. Lett. 17, 3254-3257 (2007).
89. Pang, T. et al. Small molecule antagonizes autoinhibition and activates AMPactivated protein kinase in cells. J. Biol. Chem. 283, 16051-16060 (2008).
90. Kim, C., Cheng, C.Y., Saldanha, S.A. & Taylor, S.S. PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. Cell 130, 1032-1043 (2007).
91. Taylor, S.S. et al. Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. Biochim. Biophys. Acta 1784, 16-26 (2008).
92. Yang, J. et al. Contribution of non-catalytic core residues to activity and regulation in protein kinase A. J. Biol. Chem. 284, 6241-6248 (2009).
93. Saldanha, S.A., Kaler, G., Cottam, H.B., Abagyan, R. & Taylor, S.S. Assay principle for modulators of protein-protein interactions and its application to non-ATP-competitive ligands targeting protein kinase A. Anal. Chem. 78, 8265-8272 (2006).
94. Budas, G.R., Koyanagi, T., Churchill, E.N. & Mochly-Rosen, D. Competitive inhibitors and allosteric activators of protein kinase C isoenzymes: a personal account and progress report on transferring academic discoveries to the clinic. Biochem. Soc. Trans. 35, 1021-1026 (2007).
95. Csukai, M. & Mochly-Rosen, D. Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation. Pharmacol. Res. 39, 253-259 (1999).
96. Churchill, E.N., Qvit, N. & Mochly-Rosen, D. Rationally designed peptide regulators of protein kinase C. Trends Endocrinol. Metab. 20, 25-33 (2009).
97. Silverman, R.H. Implications for RNase L in prostate cancer biology. Biochemistry 42, 1805-1812 (2003).
98. Wreschner, D.H., McCauley, J.W., Skehel, J.J. & Kerr, I.M. Interferon action- sequence specificity of the ppp(A2′p)nA-dependent ribonuclease. Nature 289, 414-417 (1981).
99. Tanaka, N. et al. Structural basis for recognition of 2′,5′-linked oligoadenylates by human ribonuclease L. EMBO J. 23, 3929-3938 (2004).
100. Tanaka, N. et al. Molecular basis for recognition of 2′,5′- linked oligoadenylates by the N-terminal ankyrin repeat domain of human ribonuclease L. Nucleic Acids Symp. Ser. (Oxf) 323-324 (2005).
101. Nakanishi, M., Goto, Y. & Kitade, Y. 2-5A induces a conformational change in the ankyrin-repeat domain of RNase L. Proteins 60, 131-138 (2005).
102. Nakanishi, M. et al. Functional characterization of 2′,5′- linked oligoadenylate binding determinant of human RNase L. J. Biol. Chem. 280, 41694-41699 (2005).
103. Thakur, C.S. et al. Small-molecule activators of RNase L with broad-spectrum antiviral activity. Proc. Natl. Acad. Sci. USA 104, 9585-9590 (2007).
104. Papa, F.R., Zhang, C., Shokat, K. & Walter, P. Bypassing a kinase activity with an ATP-competitive drug. Science 302, 1533-1537 (2003).
105. McPherson, J.D. et al. A physical map of the human genome. Nature 409, 934-941 (2001).
106. Venter, J.C. et al. The sequence of the human genome. Science 291, 1304-1351 (2001).
107. Chen, C.-H. et al. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 321, 1493-1495 (2008).
108. Okuzumi, T. et al. Inhibitor hijacking of Akt activation. Nat. Chem. Biol. 5, 484-493 (2009).
109. Sergina, N.V. et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437-441 (2007).